Killen Group’s Quest Diagnostics DGX Stock Holding History

Killen Group’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$12.5M	Sell	175,339 -17,005	-9%	-$1.14M	1.45%	22
2015 Q4	$13.7M	Sell	192,344 -98,130	-34%	-$6.6M	1.41%	24
2015 Q3	$17.9M	Sell	290,474 -73,935	-20%	-$5.17M	1.67%	15
2015 Q2	$26.4M	Sell	364,409 -57,705	-14%	-$4.26M	2%	8
2015 Q1	$32.4M	Sell	422,114 -75,541	-15%	-$5.41M	2.32%	5
2014 Q4	$33.4M	Buy	497,655 +32,000	+7%	+$2.02M	2.18%	5
2014 Q3	$28.3M	Buy	465,655 +1,000	+0.2%	+$61.6K	1.57%	13
2014 Q2	$27.3M	Buy	+464,655	New	+$27.2M	1.42%	14

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Killen Group's DGX Position: Q1 2016 in Review

Killen Group reduced its Quest Diagnostics (DGX) stake by 8.8% in Q1 2016, selling an estimated $1.14M and leaving 175,339 shares worth $12.5M. The position accounts for 1.45% of the portfolio, ranked #22.

Killen Group first reported a position in DGX in Q2 2014 and has held it in 8 quarters since. The position peaked at $33.4M in Q4 2014. 557 funds tracked by Wall St. Rank hold DGX as of Q1 2016.

Killen Group held 175,339 shares of Quest Diagnostics worth $12.5M as of Q1 2016.
Killen Group sold 17,005 Quest Diagnostics shares in Q1 2016, an estimated $1.14M.
Quest Diagnostics made up 1.45% of Killen Group's portfolio in Q1 2016, its #22 holding.
Killen Group first reported a position in Quest Diagnostics in Q2 2014 and has held it in 8 quarters since.
Killen Group's Quest Diagnostics position peaked at $33.4M in Q4 2014.
557 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2016.

Based on Killen Group's 13F filing for Q1 2016, filed 27 Apr 2016.